The aim of this study is to assess whether high intensive statin therapy could regress carotid atherosclerotic plaques as determined by High-Resolution Contrast Enhanced Magnetic Resonance imaging (CE-MRI). Enrolled patients have a baseline CE-MRI examination for screening carotid atherosclerotic plaques and are randomized to either low dose of Rosuvastatin (5mg) group or high dose of Rosuvastatin (20mg) group. After 26 weeks, all patients received CE-MRI examination again and each pair of baseline and follow-up CE-MRI assessments was analyzed in a blinded fashion. Moreover, lipid level and major adverse cardiovascular events are also evaluated during follow-up.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
150
drug intervention
drug intervention
Beijing Tiantan Hospital, Capital Medical University
Beijing, China
RECRUITINGTo evaluate whether 26 weeks of treatment with 5/20mg rosuvastatin results in regression of carotid atherosclerotic plaques as measured by CE-MRI
Time frame: 26 weeks
major adverse cardiovascular events
Time frame: 26 weeks
To evaluate the change in lipid and lipoprotein levels as assessed by percentage change from baseline.
Time frame: 26 weeks
To evaluate the change from baseline in liver function (AST/ALT) at 26 weeks
Time frame: 26 weeks
To evaluate the change from baseline in renal function (serum creatine) at 26 weeks
Time frame: 26 weeks
To evaluate the change from baseline in creatine kinase at 26 weeks
Time frame: 26 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.